[A new therapy of hemophilia with ranitidine].
20 cases of hemophilia, including ten of hemophilia A , nine of hemophilia B and one of von Willebrand's disease (VWD), were treated with ranitidine. The results revealed that the levels of both factor VIII and IX were increased and the clinical symptoms of bleeding were ameliorated. The level of factor VIII in hemophilia A ranged from 5.27 +/- 3.94% before treatment and rose to 14.68 +/- 4.70% during the treatment period (P less than 0.001). The level of the factor IX in the patients with hemophilia B increased from 4.42 +/- 3.01% before treatment to 20.33 + 9.31% under treatment (P less than 0.001). Tn the patient with VWD the level of the factor VIII rose but the level of von Willebrand factor did not change. The drug has no side effect. The results of our study suggests that ranitidine therapy is effective and safe in hemophilia.
Hu
L M
LM
Wenzhou Third Hospital, Zhejiang.
Ye
L L
LL
Xu
B
B
D000293:Adolescent; D000328:Adult; D002648:Child; D005164:Factor IX / Q000378:metabolism; D005169:Factor VIII / Q000378:metabolism; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy* / Q000378:metabolism; D002836:Hemophilia B / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011899:Ranitidine / Q000627:therapeutic use*; D014842:von Willebrand Diseases / Q000188:drug therapy
D011899:Ranitidine; D005169:Factor VIII; D005164:Factor IX